MEDICINE II: ANTI-INFLAMMATORIES, CATARACTS, AND ENDOCRINE DISEASE
Conflict of Interest The Authors have no conflicts of interest.
Disclaimer
Powdered phenylbutazonea at a concentration of 3.24 10–6 M(1mg/mL) was used in the in vitro Ussing chambers studies. A compounded product was used because this is an in vitro study and did not involve
administering the product to an animal. Various additives are added to the injectable and oral forms of phenylbutazone used commercially. It was im- portant to have pure phenylbutazone diluted to an appropriate concentration in this study.